GATA‐binding protein 3 and gross cystic disease fluid protein 15 as a potential diagnostic marker for extramammary Paget's disease
Abstract Objectives The aim of this study was to evaluate the expression of GCDFP15 and GATA‐binding protein 3 (GATA‐3) in extramammary Paget's disease (EMPD) skin and serum samples and to assess their availability as tumor markers for the diagnosis and assessment of disease severity in primary...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Wiley
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/52d6ac78eedc41268d961a26aacb651c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:52d6ac78eedc41268d961a26aacb651c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:52d6ac78eedc41268d961a26aacb651c2021-12-02T09:08:29ZGATA‐binding protein 3 and gross cystic disease fluid protein 15 as a potential diagnostic marker for extramammary Paget's disease2574-459310.1002/cia2.12193https://doaj.org/article/52d6ac78eedc41268d961a26aacb651c2021-12-01T00:00:00Zhttps://doi.org/10.1002/cia2.12193https://doaj.org/toc/2574-4593Abstract Objectives The aim of this study was to evaluate the expression of GCDFP15 and GATA‐binding protein 3 (GATA‐3) in extramammary Paget's disease (EMPD) skin and serum samples and to assess their availability as tumor markers for the diagnosis and assessment of disease severity in primary EMPD. Methods Skin samples and serum samples were obtained from 16 patients with primary EMPD (10 cases from male, six cases from female; stage IA six cases, stage IB seven cases, stage III one case, stage IV two cases). By immunohistochemistry, the expression of GCDFP15 and GATA3 was examined in skin specimens. The serum levels of GCDFP15 and GATA3 were quantified by ELISA. Results In our study, eight out of 16 patients showed positive staining for GCDFP15. In contrast, all 16 patients showed positive staining for GATA‐3. Immunohistochemical staining of EMPD skin samples showed that GATA‐3 had a higher positivity rate than GCDFP15. However, there was no correlation between serum levels of GCDFP15 or GATA‐3 and the disease stage. Conclusion Our results indicate that GCDFP15 and GATA‐3 are useful for the diagnosis of primary EMPD, but not for monitoring disease progression, and suggest that GATA‐3 is a more reliable marker than GCDFP15 for the diagnosis of primary EMPD.Soichiro KadoKoji KamiyaMeijuan JinMiho KimuraMd Razib HossainTakeo MaekawaMayumi KomineMamitaro OhtsukiWileyarticledermatologydiagnosisimmunohistochemistryPaget diseaseextramammarysensitivity and specificityDermatologyRL1-803Immunologic diseases. AllergyRC581-607ENJournal of Cutaneous Immunology and Allergy, Vol 4, Iss 6, Pp 154-158 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
dermatology diagnosis immunohistochemistry Paget disease extramammary sensitivity and specificity Dermatology RL1-803 Immunologic diseases. Allergy RC581-607 |
| spellingShingle |
dermatology diagnosis immunohistochemistry Paget disease extramammary sensitivity and specificity Dermatology RL1-803 Immunologic diseases. Allergy RC581-607 Soichiro Kado Koji Kamiya Meijuan Jin Miho Kimura Md Razib Hossain Takeo Maekawa Mayumi Komine Mamitaro Ohtsuki GATA‐binding protein 3 and gross cystic disease fluid protein 15 as a potential diagnostic marker for extramammary Paget's disease |
| description |
Abstract Objectives The aim of this study was to evaluate the expression of GCDFP15 and GATA‐binding protein 3 (GATA‐3) in extramammary Paget's disease (EMPD) skin and serum samples and to assess their availability as tumor markers for the diagnosis and assessment of disease severity in primary EMPD. Methods Skin samples and serum samples were obtained from 16 patients with primary EMPD (10 cases from male, six cases from female; stage IA six cases, stage IB seven cases, stage III one case, stage IV two cases). By immunohistochemistry, the expression of GCDFP15 and GATA3 was examined in skin specimens. The serum levels of GCDFP15 and GATA3 were quantified by ELISA. Results In our study, eight out of 16 patients showed positive staining for GCDFP15. In contrast, all 16 patients showed positive staining for GATA‐3. Immunohistochemical staining of EMPD skin samples showed that GATA‐3 had a higher positivity rate than GCDFP15. However, there was no correlation between serum levels of GCDFP15 or GATA‐3 and the disease stage. Conclusion Our results indicate that GCDFP15 and GATA‐3 are useful for the diagnosis of primary EMPD, but not for monitoring disease progression, and suggest that GATA‐3 is a more reliable marker than GCDFP15 for the diagnosis of primary EMPD. |
| format |
article |
| author |
Soichiro Kado Koji Kamiya Meijuan Jin Miho Kimura Md Razib Hossain Takeo Maekawa Mayumi Komine Mamitaro Ohtsuki |
| author_facet |
Soichiro Kado Koji Kamiya Meijuan Jin Miho Kimura Md Razib Hossain Takeo Maekawa Mayumi Komine Mamitaro Ohtsuki |
| author_sort |
Soichiro Kado |
| title |
GATA‐binding protein 3 and gross cystic disease fluid protein 15 as a potential diagnostic marker for extramammary Paget's disease |
| title_short |
GATA‐binding protein 3 and gross cystic disease fluid protein 15 as a potential diagnostic marker for extramammary Paget's disease |
| title_full |
GATA‐binding protein 3 and gross cystic disease fluid protein 15 as a potential diagnostic marker for extramammary Paget's disease |
| title_fullStr |
GATA‐binding protein 3 and gross cystic disease fluid protein 15 as a potential diagnostic marker for extramammary Paget's disease |
| title_full_unstemmed |
GATA‐binding protein 3 and gross cystic disease fluid protein 15 as a potential diagnostic marker for extramammary Paget's disease |
| title_sort |
gata‐binding protein 3 and gross cystic disease fluid protein 15 as a potential diagnostic marker for extramammary paget's disease |
| publisher |
Wiley |
| publishDate |
2021 |
| url |
https://doaj.org/article/52d6ac78eedc41268d961a26aacb651c |
| work_keys_str_mv |
AT soichirokado gatabindingprotein3andgrosscysticdiseasefluidprotein15asapotentialdiagnosticmarkerforextramammarypagetsdisease AT kojikamiya gatabindingprotein3andgrosscysticdiseasefluidprotein15asapotentialdiagnosticmarkerforextramammarypagetsdisease AT meijuanjin gatabindingprotein3andgrosscysticdiseasefluidprotein15asapotentialdiagnosticmarkerforextramammarypagetsdisease AT mihokimura gatabindingprotein3andgrosscysticdiseasefluidprotein15asapotentialdiagnosticmarkerforextramammarypagetsdisease AT mdrazibhossain gatabindingprotein3andgrosscysticdiseasefluidprotein15asapotentialdiagnosticmarkerforextramammarypagetsdisease AT takeomaekawa gatabindingprotein3andgrosscysticdiseasefluidprotein15asapotentialdiagnosticmarkerforextramammarypagetsdisease AT mayumikomine gatabindingprotein3andgrosscysticdiseasefluidprotein15asapotentialdiagnosticmarkerforextramammarypagetsdisease AT mamitaroohtsuki gatabindingprotein3andgrosscysticdiseasefluidprotein15asapotentialdiagnosticmarkerforextramammarypagetsdisease |
| _version_ |
1718398242798960640 |